Overview: Smooth Muscle Antibody IFA TestIntroduction: The Smooth Muscle Antibody IFA Test detects ASMA to diagnose autoimmune hepatitis, causing jaundice or fatigue. Aligned with 2023 AASLD guidelines, it uses immunofluorescence for high specificity, supporting liver screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in immunology for patients with suspected autoimmune hepatitis.
Other Names: ASMA IFA Assay, Anti-Smooth Muscle Antibody Test.
FDA Status: Laboratory-developed test (LDT), meeting immunology standards for diagnostic accuracy.
Historical Milestone: ASMA testing began in the 1960s with autoimmune hepatitis research. Immunofluorescence methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Detects ASMA to diagnose autoimmune hepatitis, guides treatment, and evaluates patients with jaundice or fatigue.
Test Parameters: 1. ASMA Presence 2. ASMA Titer
Pretest Condition: No fasting required. Collect serum or saliva. Report history of jaundice, fatigue, or liver symptoms.
Specimen: Serum (SST, 2-5 mL), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document jaundice, fatigue, or history of autoimmune hepatitis. Include current medications, especially immunosuppressants.
Consent: Written consent required, detailing the tests purpose, autoimmune hepatitis implications, and risks of sample collection.
Procedural Considerations: Uses indirect immunofluorescence assay (IFA) to detect ASMA and determine titers. Results are available in 1-2 days, supporting clinical decisions. Performed in laboratories, often for autoimmune hepatitis diagnosis.
Factors Affecting Result Accuracy: Sample hemolysis or improper storage can affect results. Cross-reactivity with other autoantibodies may reduce specificity.
Clinical Significance: Positive ASMA confirms autoimmune hepatitis, guiding immunosuppressive therapy. Negative results may require ANA or liver biopsy.
Specialist Consultation: Consult a hepatologist for result interpretation and treatment planning.
Additional Supporting Tests: ANA, liver function tests, or liver biopsy to confirm autoimmune hepatitis diagnosis.
Test Limitations: Non-specific for certain liver conditions; clinical correlation is needed. Sample quality affects sensitivity.
References: AASLD Autoimmune Hepatitis Guidelines, 2023; Hepatology, Manns MP, 2022.
